Etanercept in the treatment of macrophage activation syndrome.

Abstract

Macrophage activation syndrome (MAS), a recognized complication of systemic juvenile rheumatoid arthritis (sJRA), has been associated with significant morbidity and mortality. Dysregulation of macrophage-lymphocyte interactions leading to uncontrolled proliferation of highly activated macrophages and massive release of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) appears to be central to the pathogenesis of this syndrome. Until now the mainstay of therapy has been corticosteroids and cyclosporin A. We describe a patient with MAS and sJRA successfully treated with the anti-TNF agent etanercept. The outcome in this patient suggests etanercept might be an effective therapeutic agent in MAS.

• Authors: S Prahalad, K E Bove, D Dickens, D J Lovell, A A Grom
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 28 Issue 9 Pg. 2120-4 (Sep 2001) ISSN: 0315-162X [Print] Canada
• PMID: 11550985 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
• Arthritis, Juvenile (complications, diagnosis, drug therapy)
• Biopsy, Needle
• Bone Marrow (pathology)
• Child
• Drug Administration Schedule
• Drug Therapy, Combination
• Etanercept
• Follow-Up Studies
• Humans
• Immunoglobulin G (administration & dosage)
• Macrophage Activation (drug effects, physiology)
• Male
• Receptors, Tumor Necrosis Factor (administration & dosage)
• Risk Assessment
• Severity of Illness Index
• Skin (pathology)
• Syndrome
• Treatment Outcome